Arca
Skip to content
Tools
Tools

Chronic hepatitis B

Drug research and approvals for chronic hepatitis B: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 105 studies of chronic hepatitis B are recruiting on ClinicalTrials.gov, Health Canada has authorized 17 drug trials for it since 2013, FDA has 0 approved and 2 open orphan designations naming it, and the EU has 6 authorised medicines for it.

  • Recruiting worldwide: 105
  • Trials authorized in Canada: 17
  • FDA orphan approvals: 0
  • EU medicines: 6

Recruiting now

Newest posted first, of 105 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 10

Phase 3 11

Phase 2 12 of 47

Phase 1 or earlier 12 of 28

How its trials ended

883 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 205 whose ending is known, 47% met their primary endpoint, 8% missed it and 45% stopped early.

  • Completed, result not reported29533%
  • Status unknown24127%
  • Ongoing14216%
  • Met its primary endpoint9611%
  • Stopped: other or unclear405%
  • Stopped: sponsor or business decision243%
  • Missed its primary endpoint162%
  • Stopped: enrollment or feasibility162%
  • Stopped: safety71%
  • Stopped: lack of efficacy61%

Trials authorized in Canada

The 10 newest of 17; search them all in Canada trials
Oct 2, 2026A phase I, open-label, multi-center, dose escalation study to evaluate the safety, pk, and pd of AZD6750 in participants with chronic hepatitis B on standard…AZD6750AstraZeneca PharmaceuticalsPending
Jul 22, 2026A phase 2 multi-center, randomized, open-label study to assess the efficacy and safety of AHB-137 in nucleos(t)ide analogue-treated participants with chronic…AHB-137Ausperbio Therapeutics Inc.Pending
Aug 11, 2023Phase II investigator-initiated study to understand the vaccinal effect of hbsag monoclonal ab VIR-3434 in chronic hepatitis B infectionVIR-3434University Health NetworkOngoing
Aug 16, 2021A double-blind, randomized, placebo-controlled, single and multiple dose study evaluating the safety, tolerability, and pharmacokinetics of AB-836, an hbv…AB-836Arbutus BiopharmaClosed
May 7, 2021An observer-blind, randomized study with an open-label part to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous…RO7191863RochePending
Jan 21, 2021A randomized, phase 2a, multicenter, open-label, multiple-cohort study evaluating regimens containing vebicorvir in subjects with chronic hepatitis B virus…AB-729 / Vebicorvir (ABI-H0731)Assembly Biosciences IncorporatedClosed
Oct 2, 2020Phase 2, double-blind, randomized, placebo-controlled study of heptcell (adjuvanted FP-02.2) as an immunotherapeutic vaccine in treatment naïve patients with…Heptcell (adjuvanted FP-02.2)Altimmune, Inc.Ongoing
Jul 10, 2020A phase 2 randomized, open-label, parallel-group, multicenter study to assess intrahepatic and peripheral changes of immunologic and virologic markers in…JNJ-73763989/ Peginterferon ALFA-2AJohnson & JohnsonClosed
Mar 6, 2020A phase II, randomised, adaptive, open-label platform trial to evaluate efficacy and safety of multiple combination therapies in participants with chronic…RO7020531/ Entecavir/ Tenofovir disproxil fumarate/tenofovir alafenamide/…RocheClosed
Mar 29, 2019Catalyst 206: a phase 2, exploratory study evaluating the safety and antiviral efficacy of inarigivir soproxil in non-cirrhotic, hepatitis B e antigen-negative…Inarigivir soproxil (sb 9200)Spring Bank PharmaceuticalsClosed

FDA orphan designations

Approved first, then open designations, newest first
Feb 20, 2018Tenofovir exalidexTreatment of pediatric chronic hepatitis B infection (age 0 through 11 years of age)ContraVir Pharmaceuticals, Inc.Designated
Jun 17, 1991Monoclonal antibody to hepatitis B virus (human)Prophylaxis of hepatitis B reinfection in patients undergoing liver transplantation secondary to end-stage chronic hepatitis B infection.Protein Design Labs, Inc.Designated

Medicines authorised in the EU

Newest first
Sep 25, 2017Entecavir AccordEntecavir · genericAccord Healthcare S.L.U.EMA ↗
Sep 18, 2017Entecavir Viatris (previously Entecavir Mylan)Entecavir · genericViatris LimitedEMA ↗
Jan 9, 2017VemlidyTenofovir alafenamideGilead Sciences Ireland UCEMA ↗
Oct 23, 2009Lamivudine TevaLamivudine · genericTeva B.V.EMA ↗
Jun 26, 2006BaracludeEntecavirBristol-Myers Squibb Pharma EEIGEMA ↗
Jul 29, 1999ZeffixLamivudineGlaxoSmithKline Trading Services LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.